Last Updated : January 22, 2018
Details
FilesGeneric Name:
Pembrolizumab
Project Status:
Complete
Therapeutic Area:
classical Hodgkin Lymphoma (cHL)
Manufacturer:
Merck Canada Inc.
Brand Name:
Keytruda
Project Line:
Reimbursement Review
Project Number:
PC0109-000
NOC Status at Filing:
Pre NOC
Strength:
50 mg/vial
Tumour Type:
Lymphoma
Indications:
classical Hodgkin Lymphoma (cHL)
Funding Request:
As monotherapy is indicated for the treatment of adult patients with refractory or relapsed classical Hodgkin lymphoma (cHL) who have failed autologous stem cell transplant (ASCT) and brentuximab vedotin (BV) or who are not ASCT candidates and have failed BV
Pre Noc Submission:
Yes
Sponsor:
Merck Canada Inc.
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Requested and Granted
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
pERC Meeting:
Final Recommendation Issued:
Files
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
Last Updated : January 22, 2018